Molina Healthcare, Inc.

NYSE:MOH Stock Report

Market Cap: US$17.0b

Molina Healthcare Valuation

Is MOH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MOH ($293.52) is trading below our estimate of fair value ($666.06)

Significantly Below Fair Value: MOH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOH?

Key metric: As MOH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MOH. This is calculated by dividing MOH's market cap by their current earnings.
What is MOH's PE Ratio?
PE Ratio14.7x
EarningsUS$1.14b
Market CapUS$16.96b

Price to Earnings Ratio vs Peers

How does MOH's PE Ratio compare to its peers?

The above table shows the PE ratio for MOH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.2x
HUM Humana
20.9x11.5%US$28.9b
CNC Centene
9.8x3.4%US$30.0b
HQY HealthEquity
84.9x39.8%US$7.9b
ELV Elevance Health
13.2x12.5%US$84.9b
MOH Molina Healthcare
14.7x14.7%US$17.0b

Price-To-Earnings vs Peers: MOH is good value based on its Price-To-Earnings Ratio (14.7x) compared to the peer average (32.2x).

Price to Earnings Ratio vs Industry

How does MOH's PE Ratio compare vs other companies in the US Healthcare Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
THC Tenet Healthcare
3.8x-39.2%US$12.12b
NEUE NeueHealth
1.2xn/aUS$33.51m
IDXG Interpace Biosciences
2.4xn/aUS$10.60m
FZMD Fuse Medical
2.2xn/aUS$8.67m
MOH 14.7xIndustry Avg. 21.6xNo. of Companies10PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MOH is good value based on its Price-To-Earnings Ratio (14.7x) compared to the US Healthcare industry average (21.6x).

Price to Earnings Ratio vs Fair Ratio

What is MOH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.7x
Fair PE Ratio34.9x

Price-To-Earnings vs Fair Ratio: MOH is good value based on its Price-To-Earnings Ratio (14.7x) compared to the estimated Fair Price-To-Earnings Ratio (34.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$293.52
US$364.63
+24.2%
9.0%US$414.85US$309.00n/a14
Dec ’25US$297.90
US$369.20
+23.9%
8.0%US$414.85US$309.00n/a14
Nov ’25US$326.75
US$370.13
+13.3%
7.8%US$414.85US$309.00n/a14
Oct ’25US$341.91
US$374.56
+9.5%
6.5%US$414.85US$335.00n/a14
Sep ’25US$349.79
US$372.56
+6.5%
7.1%US$414.85US$332.00n/a14
Aug ’25US$346.19
US$368.28
+6.4%
8.5%US$414.85US$315.00n/a14
Jul ’25US$292.16
US$389.59
+33.3%
9.5%US$442.00US$320.00n/a15
Jun ’25US$314.58
US$400.98
+27.5%
7.2%US$442.00US$354.00n/a15
May ’25US$338.87
US$404.27
+19.3%
7.0%US$442.00US$354.00n/a14
Apr ’25US$404.20
US$422.55
+4.5%
7.3%US$474.00US$357.00n/a14
Mar ’25US$387.21
US$417.29
+7.8%
7.4%US$474.00US$357.00n/a13
Feb ’25US$355.21
US$393.38
+10.7%
6.9%US$457.00US$357.00n/a13
Jan ’25US$361.31
US$375.42
+3.9%
7.9%US$417.00US$315.00n/a12
Dec ’24US$362.76
US$364.25
+0.4%
7.0%US$417.00US$315.00US$297.9012
Nov ’24US$336.83
US$362.17
+7.5%
6.7%US$417.00US$315.00US$326.7512
Oct ’24US$327.89
US$351.50
+7.2%
7.6%US$403.00US$290.00US$341.9114
Sep ’24US$310.44
US$351.40
+13.2%
7.3%US$403.00US$290.00US$349.7915
Aug ’24US$302.01
US$349.67
+15.8%
7.3%US$403.00US$290.00US$346.1915
Jul ’24US$301.24
US$346.47
+15.0%
7.8%US$400.00US$290.00US$292.1615
Jun ’24US$282.97
US$350.14
+23.7%
7.8%US$400.00US$290.00US$314.5814
May ’24US$305.50
US$356.79
+16.8%
7.3%US$402.00US$290.00US$338.8714
Apr ’24US$267.49
US$353.86
+32.3%
8.7%US$389.00US$282.00US$404.2014
Mar ’24US$273.80
US$357.79
+30.7%
6.6%US$389.00US$307.00US$387.2114
Feb ’24US$311.75
US$371.29
+19.1%
4.8%US$400.00US$340.00US$355.2114
Jan ’24US$330.22
US$377.43
+14.3%
6.2%US$420.00US$340.00US$361.3114
Dec ’23US$334.83
US$377.43
+12.7%
6.2%US$420.00US$340.00US$362.7614

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 22:45
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Molina Healthcare, Inc. is covered by 36 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hua HaBaird
Joshua RaskinBarclays
Andrew MokBarclays